Pay in 4 interest-free payments of $7.05 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
We believe in continuous support and monitoring to ensure the effectiveness of the treatment
Dysesthesia Incidence: Retatrutide 9mg: 8.8% Retatrutide 12mg: 20.9% Placebo: 0.7% Importantly, Eli Lilly reported that: Dysesthesia events were generally mild They infrequently led to discontinuation The mechanism is not yet fully understood This side effect was not observed in Phase 2 trials The appearance of dysesthesia at higher doses suggests it may be dose-dependent
Scientific investigations have explored its effects on melanocortin receptor physiology, neurotransmitter signaling, and neurobehavioral pathways
it should always appear as a clear, colorless solution free from visible particles or discoloration
US$ 29.36
US$ 25.55
US$ 29.73
